Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01953640 · ClinicalTrials.gov registry record
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
A clinical trial of Prostate Adenocarcinoma and Metastatic Prostate Carcinoma, sponsored by Mayo Clinic.
- Active
- Registry status
- 92
- Enrollment target
- 3
- Study locations
NCT01953640 is a study of Prostate Adenocarcinoma and Metastatic Prostate Carcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 92 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (58% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01953640, a study of Prostate Adenocarcinoma and Metastatic Prostate Carcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 92 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research trial studies gene expression in patients with prostate cancer that has spread to other places in the body receiving cytochrome P450 17 alpha hydroxylase/17,20 lyase (CYP-17) inhibition therapy. Studying samples of tissue, blood, and urine in the laboratory from patients receiving CYP-17 inhibition therapy may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer. It may also help doctors understand how well patients respond to treatment.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
Study Locations (3)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2013-05-30 |
| Est. Completion | 2026-12-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01953640
The ClinicalTrials.gov registry entry for NCT01953640 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (58% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Quality-of-Life Assessment is the first listed.
NCT01953640 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01953640 about?
NCT01953640 is a clinical study titled "Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy". This research trial studies gene expression in patients with prostate cancer that has spread to other places in the body receiving cytochrome P450 17 alpha hydroxylase/17,20 lyase (CYP-17) inhibition therapy. Studying samples of tissue, blood, and urine in the laboratory from patients receiving CYP-...
What is the current status of trial NCT01953640?
This trial is currently active not recruiting. The enrollment target is 92 participants. The study started on 2013-05-30. Estimated completion is 2026-12-15.
What conditions does trial NCT01953640 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Hormone-Resistant Prostate Cancer.
What interventions are being tested in trial NCT01953640?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT01953640?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01953640 being conducted?
This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
RECRUITING · Early Phase 1
-
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
RECRUITING · NA
-
Customized TULSA-PRO Ablation Registry
RECRUITING
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.